The drugs like Combiflam and D Cold Total are used by many of us very often. But these drugs have failed to meet the required standard. As per the recent report published by Central Drugs Standard Control Organization (CDSCO), around 60 drugs were declared substandard in its test done in March 2017.
This is surely awful news for all users who take these drugs to get rid of their ailments. Combiflam is sold by Sanofi India while D Cold Total is produced and sold by Reckitt Benckiser India.
Reportedly, other drugs like Oflox 100 and Theo Asthalin sold by Cipla are found to be substandard. Cadilose solution by Cadila also falls in the same row.
The drug regulatory body CDSO has sent notices to all companies who manufacture these 60 medicines and sell in the market.
Sanofi’s Combiflam with batch number A151195 failed to pass the disintegration test of CDSCO. This batch was produced in October 2015. This is not the first time; they are found guilty several times. Last year, this drug was found to be substandard three times in February, April and in June. After this incident, Sanofi India had called out the affected batches which failed the test.
Briefing to the media, the Sanofi spokesperson said that we would take proper action once we receive confirmation from CDSCO.
CDSCO check some parameters on a regular basis to find whether companies are following the required standard or not. Among these parameters, one is to check the breakdown of the tablet in the human body. It spotted these batches in March 2017 and found that these were also manufactured in 2015.
The Sanofi officials said that after the last year case, they had taken proper corrective action to ensure that the drugs pass the test. He further clarified that even after failing the test, there was no impact on safety and efficacy of the drugs. Indian users are using Combiflam since 25 years and this has proved to be a safe drug to get rid of their pain.
Similarly, Cipla’s Theo Asthalin and Oflox have failed this test done by CDSCO. D Cold Total with batch no AD762 was also unable to pass this test last month.
Indians often use these drugs and such news is really very sad. These companies are playing with health and safety of common people. The side effects of these medicines may overweigh the benefits. Their sales in the Indian market are too high. The annual sale of Combiflam is Rs. 169.2 crore. Cipla’s Theo Asthalin and Oflox’s annual sales are 17.3 and 20.7 crores respectively.